“ The mission of Drugs For Neglected Diseases initiative (DNDi) is to improve the quality of life and the health of people suffering from neglected diseases. SCYNEXIS has played a key role in advancing the best technology for the most neglected.
”
- Dr. Bernard Pécoul, DNDi Executive Director
Medicinal Chemistry
Biological Screening
In Vitro Pharmacology
ADMET-PK / Bioanalytical
cGMP & Process Chemistry
Innovative Drug Pipeline Solutions SCYNEXIS delivers innovative and integrated drug discovery and development solutions to our pharmaceutical and global health partners. Our success is demonstrated by the eleven pre-clinical and clinical drug candidates that we have delivered over the last five years including SCYNEXIS’ anti-HCV clinical compound, SCY-635, from our proprietary cyclophilin inhibitor technology platform. Our expertise is offered on a fee-for-service basis or in a shared-risk arrangement.
Please join SCYNEXIS in supporting DNDi in its efforts to find cures for tropical diseases such as sleeping sickness, leishmaniasis and Chagas disease.
From Concept To Clinic With Speed And Innovation™ w w w. s c y n e x i s . c o m
SCYNEXIS, Inc. Research Triangle Park, NC Email:
[email protected] Phone: +1.919.544.8600
